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Abstract
The etiology of respiratory distress syndrome (RDS) is multifactorial and multigenic. Studies have suggested that polymorphisms 
and mutations in the surfactant protein B (SP-B) gene are associated with the pathogenesis of RDS. The objectives of this 
study were to determine and compare the frequencies of SP-B gene polymorphisms in preterm babies with and without RDS. 
We studied 151 neonates: 79 preterm babies without RDS and 72 preterm newborns with RDS. The following four SP-B gene 
polymorphisms were analyzed: A/C at -18, C/T at 1580, A/G at 9306, and G/C at nucleotide 8714. The polymorphisms were 
detected by PCR amplification of genomic DNA and genotyping. The genotypes were determined using PCR-based converted 
restriction fragment length polymorphisms. The control group consisted of 42 (53%) girls and 37 (47%) boys. Weight ranged 
from 1170 to 3260 g and mean gestational age (GA) was 33.9 weeks (range: 29 to 35 weeks and 6 days). The RDS group 
consisted of 31 (43%) girls and 41 (57%) boys. Weight ranged from 614 to 2410 g and mean GA was 32 weeks (range: 26 to 
35 weeks). The logistic regression model showed that GA was the variable that most contributed to the occurrence of RDS. 
The AG genotype of the A/G polymorphism at position 9306 of the SP-B gene was a protective factor in this population (OR 
= 0.1681; 95%CI = 0.0426-0.6629). We did not detect differences in the frequencies of the other polymorphisms between the 
two groups of newborns. 
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Pulmonary surfactant is a lipid-protein complex essential 
for normal lung function. It is responsible for decreasing the 
surface tension of the air-liquid interface of the alveoli, thus 
preventing lung collapse at the end of expiration (1). 
The surfactant is a mixture of lipids (~90%) and pro-
teins (~10%) with phospholipids representing 80-90% of 
surfactant lipids. Phosphatidylcholine is the most prevalent, 
accounting for 70-80% of the total. Dipalmitoylphosphatidyl-
choline (DPPC) represents about 60% of the phospholipids 
and is the principal surface tension-lowering component of 
pulmonary surfactant (2). The following four proteins are 
associated with the surfactant complex: SP-A, SP-B, SP-C, 
and SP-D. They play important roles in surfactant function 
and metabolism (3). 
In 1959, Avery and Mead (1) showed that pulmonary 
surfactant deficiency is a major factor in the pathophysiology 
of respiratory distress syndrome (RDS). The incapacity of 
the premature baby to produce surfactant in an appropriate 
quantity and the structural immaturity of the lung constitute 
the primary etiologies of RDS (1). The incidence of RDS 
increases with decreasing gestation period, with about 25% 
of babies affected at 34 weeks of gestation and up to 80% 
of babies affected at less than 28 weeks (4).
In spite of pulmonary surfactant replacement therapy 
and/or other therapies (maternal steroids treatment), RDS 
remains a cause of concern. The etiology of RDS is mul-
tifactorial and multigenic, and genetics may play a role in 
its pathogenesis (5,6). The surfactant protein genes have 
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been used as candidate genes in the study of the genetics 
of RDS. The presence of polymorphisms and mutations in 
the protein B gene has been implicated in RDS (6-8).
SP-B is a hydrophobic protein secreted by type II cells 
in the lung and is essential for normal pulmonary function 
(9,10). It is required for synthesis of lamellar bodies and for 
the reduction of surface tension at the air-liquid interface. 
SP-B is necessary for the formation of the lungs and of 
tubular myelin, as well as for the processing of SP-C. The 
absence of SP-B in animals and humans results in respira-
tory failure and death shortly after birth (11-15). 
Several studies have evaluated the association of SP-A 
and SP-B gene polymorphisms with RDS (16-21), but the 
functional consequences of the allelic variations of the SP 
genes are not well understood, and clarification of genetic 
diversity is a challenge for the future (6).
The study of the polymorphisms/mutations of surfactant 
proteins can help to understand individual variability in the 
susceptibility to pulmonary diseases. These genetic vari-
ants can be valuable markers in the mapping of several 
pathologies, particularly RDS. The objectives of the present 
study are to determine the frequencies of four SP-B gene 
polymorphisms (A/C at nucleotide -18, C/T at nucleotide 
1580, A/G at nucleotide 9306, and G/C at nucleotide 8714) in 
Brazilian preterm babies with and without RDS, to compare 
the polymorphism frequencies between the two groups and 
to evaluate differences related to gender, race and RDS.
Material and Methods
Study population
This was a case-control study in which the samples 
and information were prospectively collected. We studied 
151 neonates classified into two groups, preterm newborns 
without RDS and preterm newborns with RDS. The first 
group consisted of 79 preterm newborns with no respiratory 
distress; 42 (53%) were girls and 37 (47%) were boys, 34 
(43%) were black, 16 (20%) were white, and 29 (37%) were 
non-black/non-white. Weight ranged from 1170 to 3260 g 
(mean: 1828 g), and gestational age ranged from 29 to 35 
weeks and 6 days (mean: 33.9 weeks).
The RDS group consisted of 72 preterm neonates; 31 
(43%) were girls and 41 (57%) were boys, 32 (44%) were 
black, 9 (13%) were white, and 31 (43%) were non-black/
non-white. Weight ranged from 614 to 2410 g (mean: 1518 
g) and mean gestational age was 32 weeks (range: 26 to 
35 weeks; Table 1). 
The data of the newborns and their mothers were col-
lected at the same time when informed written consent 
was obtained.
Patients were classified according to ethnicity, gesta-
tional age, and gender. Ethnicity was based on the parents’ 
characteristics (shape of nose, mouth, skin color, kind of 
hair). Premature newborns were divided into three groups 
according to gestational age: newborns aged 26 to 30 
weeks, 31 to 33 weeks and 6 days, and 34 to 35 weeks 
and 6 days.
The study protocol was approved by the Ethics Com-
mittees of the following participating centers: Maternidade 
Climério de Oliveira, Universidade Federal da Bahia, and 
Maternidade Prof. José Maria de Magalhães Neto, Salvador, 
BA, Brazil, from February 2009 to April 2010. 
Inclusion criteria
The newborns were divided into two groups: preterm 
newborns without RDS = gestational age between 26 and 
35 weeks and 6 days; RDS group = preterm newborns with 
RDS and gestational age between 26 and 35 weeks and 
6 days. The diagnosis of RDS was based on the following 
clinical and radiological criteria: signs and symptoms of 
respiratory distress (grunting, intercostal retraction, nasal 
flaring, cyanosis and tachypnea), chest radiographs with a 
diffuse reticulogranular pattern, and air bronchograms. 
Exclusion criteria
Preterm newborns with other diseases, genetic syn-
dromes, congenital malformations, and other associated 
pathologies were excluded.
Laboratory tests
Blood sample collection. Blood collection was performed 
at the hospital at the same time as other routine exams. 
Blood samples were placed in tubes containing EDTA and 
kept at 4°C until DNA extraction. 
DNA extraction and PCR amplification. The genomic 
DNA of the newborns was purified from total blood using 
the Wizard Genomic DNA Purification Kit® (Promega, USA) 
Table 1. Clinical features of preterm newborns with and without 
respiratory distress syndrome (RDS). 
Clinical features Without RDS 
(N = 79)
With RDS 
(N = 72)
Gender, N (%)
Female 42 (53) 31 (43)
Male 37 (47) 41 (57)
Race, N (%)
Black 34 (43) 32 (44)
White 16 (20)  9 (13)
Non-black/non-white 29 (37) 31 (43)
Weight (g) - mean 1828 1518
Minimum 1170  614
Maximum 3260 2410
Gestational age* (mean) 33.9 32
Minimum 29.0 26
Maximum 35.9 35
*Gestational age was determined by the Ballard method (22).
68 P.P.R. Lyra et al.
www.bjournal.com.brBraz J Med Biol Res 44(1) 2011
according to manufacturer instructions. DNA from patient 
and healthy newborn blood samples was amplified by PCR 
amplification protocols, as described by Lin et al. (23).
A DNA sequence of 10,751 spanning all SP-B genes, 
including the 5’ and 3’ flanking regions, was amplified 
using the Expand Long Template PCR system (Roche, 
Germany). The primers used were specific for SP-B, sense 
primer 536 and antisense primer 535. The PCR mixture 
(total volume of 50 µL) consisted of 100 ng/µL DNA, 1X 
PCR buffer, 2.0 mM MgCl2, 1.5 mM deoxyribonucleotide 
triphosphates (dNTPs) (Promega®), 150 ng sense primer 
536 and anti-sense primer 535, and 0.75 µL of the Expand 
enzyme. PCR cycles consisted of one cycle at 95°C for 2 
min, followed by 10 cycles at 95°C for 30 s, 58°C for 1 min 
and 72°C for 10 min and then by 20 cycles at 95°C for 30 
s, 62°C for 10 min and 68°C for 12 min, with a final 20-min 
extension (68°C).
For amplification of the segments that span the poly-
morphisms mentioned previously, we used previously 
described primers and protocols (23,24). All primers used 
are listed in Table 2. 
The PCR product obtained in the first PCR assay was 
used as a substrate for amplification of 
fragments with polymorphic sites (Table 
3). The PCR mixture (total volume 30 
µL) consisted of 1 µL of the 11-kb PCR 
products, 0.2 µM of each primer, 0.15 
mM dNTPs, 1X PCR buffer, and 0.15 µL 
AmpTaq (Roche). The cycles consisted 
of 95°C for 2 min followed by 5 cycles of 
95°C for 30 s, 50°C for 1 min, and 70°C 
for 1 min and 30 cycles of 95°C for 30 s, 
55°C for 1 min, and 70°C for 1 min. The 
final extension was at 72°C for 2 min.
Genotyping of SP-B polymorphisms 
We analyzed the following four SP-B 
polymorphisms: A/C at nucleotide -18, 
C/T at nucleotide 1580, A/G at nucleotide 
9306, and G/C at 8714. The genotypes 
were defined based on the analysis of the PCR products 
obtained from the restriction enzyme reactions [PCR-
based converted restriction fragment length polymorphism 
(cRFLP)], as described by Lin et al. (23,24). Six microliters 
of the second PCR product was subjected to digestion with 
the restriction enzymes ApalI, HinfI, DdeI, and BfaI accord-
ing to manufacturer specifications. The digested products 
were identified on 8 or 10% polyacrylamide gel. 
Statistical analysis
Descriptive statistics were used to describe the categori-
cal and numerical variables of the newborns’ characteristics. 
Frequency distribution for categorical variables, central trend 
measures and variability measures for numerical variables 
were also used. 
The Fisher exact test was applied to polymorphism 
frequency data. Logistic regression analyses and the 
odds ratio were calculated to detect the contribution of the 
studied variables (multivariable estimative for the linear 
coefficients) to the development of RDS. The confidence 
interval was set at 95%.
In the logistic model for gestational age, the reference 
Table 2. Primers used in the study. 
Primers Direction Sequence 5’ ⇒ 3’
535 Anti-sense GCGACTAGTCTATGACGTCTGCTTCTCTGCCAAGGGAGT
536 Sense GCGGTCGACTCATCATGGTACTAATTTGCCCGTCCA
556 Sense GTCCAGCTATAAGGGGCCGTG
95A Anti-sense GTGAGTGGTGAGCTGCCTA
133 Sense CTCGAATTCACTCGTAACTCCAGCACCC
584 Anti-sense GTGAGCTTGCAGCCCTCTCA
101 Sense CTCGAATTCAGGACATACACACAGTCCCT
102 Anti-sense CCAGCTGAGCTTTCAGCAGA
557 Sense CTGTGTAATACAATGTCTGCACTA
121 Anti-sense CTCGAATTCTGCTGGATTGCAGGTGTGA
Nucleotide positions are according to Ref. 25. The sequences of the primers are from 
Refs. 23 and 24.
Table 3. Location of polymorphism sites of the SP-B gene. 
Polymorphism Gene location Nucleotide Primers PCR fragment size Restriction enzyme
Position Change
A/C -18 5’ flanking 18 A/C 556/95A 167 bp ApalI
C/T 1580 Exon 4 1580 C/T 133/584 270 bp DdeI
A/G 9306 3’UTR 9306 A/G 557/121 129 bp BfaI
G/C 8714 3’UTR 8714 G/C 101/102 784 bp HinfI
Nucleotide positions are according to Ref. 25. The sequences of the primers have been described in Refs. 23 and 24 
and are given in Table 2.
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category was 26 to 30 weeks and 6 days; for the 
gender variable, female; for race, black; for the 
G/C 8714 polymorphism, the GG genotype; for 
the C/T 1580 polymorphism, the CC genotype, 
and for the A/G 9306 and A/C -18 polymorphisms, 
the AA genotype.
Results
Twenty (27%) mothers in the group without 
RDS had premature rupture of membranes, 27 
(36%) had gestational hypertension, 6 (8%) had 
chronic hypertension, 2 (3%) had diabetes mel-
litus, 15 (21%) had urinary tract infection, and 4 
(5%) had other diseases. Among the mothers of 
the RDS group, 17 (25%) had premature rupture 
of membranes, 19 (28%) had gestational hypertension, 
16 (24%) had chronic hypertension, 2 (3%) had diabetes 
mellitus, 9 (13%) had urinary tract infection, and 5 (7%) 
had other medical conditions. Thirty-eight (48%) mothers in 
the control group and 41 (57%) mothers in the RDS group 
used antenatal steroids.
Polymorphism analysis 
Analysis of A/G 9306 polymorphism using the logistic 
regression model showed that gestational age was the most 
important factor for occurrence of the disease and the AG 
genotype was a protective factor against RDS (OR = 0.1681; 
95%CI = 0.0426-0.6629; Tables 4 and 5). Figure 1 shows 
the frequencies of the polymorphisms in each group.
The analysis of the G/C 8714, C/T 1580, and A/C -18 
Figure 1. Frequencies of the A/G 9306 SP-B genotypes. Comparison between the respiratory distress syndrome 
(RDS) group (preterm newborns with RDS) and the control group (preterm newborns without RDS).
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Table 4. Logistic regression analysis of the A/G 9306 polymorphism. 
Coefficients Estimate Standard error z-value “Pr(>|z|)”
(“Intercept”) 2.0808 0.8836 2.355 0.018532 
GA 31-33.9 weeks -1.5708 0.8770 -1.791 0.07328
GA 34-35.9 weeks -3.6319 0.9453 -3.842 0.00012
Gender - male 0.5259 0.4681 1.123 0.26129
Race - white -0.5539 0.6474 -0.856 0.392261
Race - NW/NB -0.1016 0.5117 -0.199 0.842556
A/G -1.7833 0.7001 -2.547 0.010858
G/G -0.8687 0.7869 -1.104 0.269633
GA = gestational age; NW/NB = non-white/non-black.
Table 5. Odds ratio of the A/G 9306 polymorphism. 
OR IL 95%CI SL 95%CI P
GA 31-33.9 weeks 0.2079 0.0373 1.1596
GA 34-35.9 weeks 0.0265 0.0041 0.1688 0.0001
Gender - male 1.6919 0.6759 4.2350
Race - white 0.5747 0.1616 2.0442
Race - NW/NB 0.9034 0.3313 2.4629
A/G 0.1681 0.0426 0.6629
G/G 0.4195 0.0897 1.9614
OR = odds ratio; IL 95%CI = inferior limit confidence interval; SL 
95%CI = superior limit confidence interval; GA = gestational age; 
NW/NB = non-white/non-black. 
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polymorphisms demonstrated no association between the 
genotypes from these polymorphic sites and RDS, gender 
or race. 
Discussion
RDS is caused by primary surfactant deficiency and is 
the most frequent form of respiratory insufficiency in the 
preterm newborn. Despite advances in treatments with 
antenatal steroids, exogenous surfactant and mechanical 
ventilation, this disease is still a major cause of morbidity 
in this group of patients (4,26,27). Pulmonary morbidity 
has been attributed to oxygen toxicity, barotrauma, lung 
immaturity, and nutritional deficiencies. However, significant 
variations in pulmonary outcomes of similar infants with 
comparable exposures to oxygen, mechanical ventilation 
and nutritional deficiencies suggest that genetic factors also 
contribute to pulmonary outcomes (28). RDS is the result 
of complex interactions between several environmental 
and genetic factors associated with prematurity, gender, 
race, and maternal diseases (6). Some genetic variants of 
surfactant proteins, particularly SP-A and SP-B, are risk or 
protective factors in RDS etiology (13,16,17,29). 
The present study determined the frequency of four SP-B 
polymorphisms (G/C at nucleotide 8714, C/T at nucleotide 
1580, A/G at nucleotide 9306, and A/C at nucleotide -18) 
in 79 preterm babies without RDS and 72 preterm babies 
with RDS in a Brazilian population of the city of Salvador, 
Bahia, and the association of these polymorphisms with 
gender and race. 
The results of our study showed that gestational age 
was the most important factor for the occurrence of RDS 
in the AG 9306 polymorphism (Tables 4 and 5) and also in 
the other three polymorphisms (data not shown). 
 The incidence of RDS increases with decreasing 
gestational age, with about 25% of babies affected at 34 
weeks of gestation and up to 80% of babies affected at 
less than 28 weeks (4). This can be explained by the fact 
that premature babies are unable to produce appropriate 
amounts of surfactant and by  the structural immaturity of 
the lungs at lower ages (1).
The G/C 8714 polymorphism is located in the 3’UTR 
of the SP-B gene, corresponding to the flanking region. 
Although it is located outside the protein translation site, 
this region can somehow impact gene expression and/or 
protein function (24). 
In our study, there was no statistically significant differ-
ence in the distribution of the genotypes of the G/C poly-
morphism at nucleotide 8714 in patients with and without 
RDS. In 2007, we studied the same four polymorphisms 
in a group of 100 healthy term babies and a group of 50 
preterm babies with RDS (30). When race was analyzed 
separately, among the white individuals, the GG genotype 
was only found in the RDS group. These findings suggested 
that the GG genotype might be a risk factor for RDS, and 
the GC genotype might be a protective factor. In a study of 
patients with alveolar proteinosis, Lin et al. (24) analyzed a 
family in whom 14 newborns died due to early respiratory 
insufficiency. The G/C polymorphism at nucleotide 8714 
did not have a pathophysiological impact in this population. 
Therefore, our results should be analyzed with caution. 
They reinforce the need for other studies in the Brazilian 
population to define the real role of this genotype in RDS. 
The C/T polymorphism at nucleotide 1580 is located 
at the end of exon 4 at nucleotide 1580 and can alter the 
translation of amino acid 131 by substitution of threonine 
(ACT) with isoleucine (ATT) (23). This change eliminates 
a potential N-linked glycosylation site but the real con-
sequences of this alteration are not known (7,31). In the 
literature, most studies suggest that the C/C genotype 
might be associated with a greater risk of developing RDS 
and other pulmonary diseases. In our study, we did not find 
any statistically significant difference in the frequencies of 
genotypes CC, CT, and TT when the healthy term group 
and the RDS group were compared. Although genotype 
CC was more frequently found in the RDS group than 
in the control group, this difference was not statistically 
significant (Table 4). 
The A/G polymorphism at nucleotide 9306 is located in 
the 3’UTR. In our study, we found that the AG genotype of 
the A/G polymorphism was protective against RDS in the 
population studied (OR = 0.17). This result differs from a 
study by another laboratory where the AG genotype was 
considered to be a risk factor for RDS (7). In our 2007 study 
on a population of healthy term and preterm newborns from 
the city of São Paulo, we did not find a protective effect of 
the AG genotype (30). 
The different results between our studies and others 
might be attributed to ethnic differences or to sample 
size. Liu et al. (32) have reported that ethnic background 
is an important risk factor in analytical studies of allele 
and genotype frequencies. They analyzed the similarity 
of genetic markers among populations of three different 
ethnic groups (Caucasian, Black, and Hispanic), in order 
to observe whether individuals of different races or ethnic 
groups could be grouped together in linkage studies. The 
results showed that the allele and genotype frequencies can 
differ between distinct ethnic groups, especially between 
ethnic groups of different races (32). 
The Brazilian population is one of the most heteroge-
neous populations in the world, originating from the mis-
cegenation of Indians, blacks and whites. The distribution 
of these three different ethnic groups in the territory did 
not occur in a homogeneous way. In the city of Salvador, 
in particular, there is a higher prevalence of individuals of 
African descent, as well as miscegenation of individuals of 
other backgrounds. 
The analysis of the interaction between SP-A and SP-B 
might be useful for the evaluation of risk to develop RDS in 
patients with the A/G 9306 genotype (7). Since our study 
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did not evaluate SP-A polymorphisms, we were unable to 
analyze the SP-A and SP-B interaction. Recently, Wambach 
et al. (33) also suggested that reduced SP-C transcription 
contributes to the genetic risk for neonatal RDS in devel-
opmentally susceptible infants.
The A/C -18 polymorphism is located in the 5’UTR 
and may impact the initiation of mRNA transcription. In 
the case-control study of Floros et al. (18), the association 
of SP-A and SP-B polymorphisms was evaluated in white 
and African-American newborns with RDS. The authors 
found a higher frequency of the AA genotype of the A/C 
-18 polymorphism in African-American neonates. This 
observation was made in preterm newborns with RDS 
and gestational age between 28 and 31 weeks (7). In our 
study, we found that the AA genotype was high in the RDS 
population but not significantly so. We could not detect a 
statistically significant difference in the distribution of the 
genotypes of the A/C -18 polymorphism between healthy 
term newborns and the RDS groups.
The present study demonstrated that the AG genotype 
of the AG 9306 polymorphism was a protective factor 
against the development of RDS. The other polymorphisms 
studied (G/C at 8714, C/T at 1580, A/C at -18) were not 
associated with RDS. 
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